Navigation Links
Safety and Efficacy of OrbusNeich's Genous™ Stent Demonstrated in High-Risk Patients with Known Contraindications for Dual Antiplatelet Therapy
Date:1/10/2011

HONG KONG, Jan. 10, 2011 /PRNewswire/ -- Data from patients who are considered high-risk due to underlying clinical conditions and who cannot be treated with drug eluting stents (DES) and the accompanying requirement of long-term dual antiplatelet therapy (DAPT) showed positive safety and short- and long-term clinical outcomes following treatment with OrbusNeich's Genous Stent, according to a study published online in EuroIntervention (published-ahead-of-print, August 2010).  

Known contraindications for DAPT include hypersensitivity or allergy to aspirin, a hemorrhagic risk, or a planned surgery shortly after percutaneous coronary intervention (PCI) that would require cessation of DAPT.

In the study, the major adverse cardiac events (MACE) free survival rate in patients treated with the Genous Stent was 80.6% after one year.  Between year one and year two, no additional MACE were observed. In patients who underwent surgical treatment shortly after PCI, no perioperative MACE or thrombotic events occurred.  Despite a very short period of DAPT use of 15 to 30 days, there were no cases of sub-acute, late or very late stent thrombosis in treated patients. The cumulative incidence of cardiac death was 1.6%, which is low considering the high risk patient population.

"The Genous Stent is an important and extremely attractive option for interventional cardiologists to safely manage high-risk patients who are contraindicated for prolonged DAPT and, therefore, should not receive a DES," said Paolo Scacciatella, M.D., Ph.D., of the Molinette Hospital Turin, Italy, and principal investigator of the study.  "This is the first study that demonstrates the feasibility and efficacy of the Genous Stent in this particular segment of patients who are challenging to treat."

Emanuele Meliga, M.D., Ph.D., FESC, of Ordine Mauriziano Hospital in Turin, Italy, and corresponding author of the publication added, "We have observe
'/>"/>

SOURCE OrbusNeich
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Potential Safety Issue Identified in Ongoing Phase 2 Clinical Study of HCV-796
2. Lpath Demonstrates Strong Safety Profile of Lead Drug Candidate, Sphingomab(TM), in Non-Human Primates
3. Cypher(R) Sirolimus-Eluting Coronary Stent Demonstrates Sustained Clinical Benefits Compared to Bare Metal Stents in Five-Year Randomized Clinical Trial With No Differences in Long-Term Safety
4. Five-Year Data From Taxus II Clinical Trial Highlights Safety and Efficacy of Taxus(R) Stent Compared to Bare-Metal Stent
5. Two-Year Outcomes From Large Head-to-Head Clinical Trial Indicate Similar Safety Profile in Diabetic Patients for Cypher(R) Sirolimus-Eluting Coronary Stent and Taxus Stent
6. Iomai Launches Phase 1/2 Safety Study of Dose-Sparing Patch for Use With Pandemic Influenza Vaccine
7. R7128 Demonstrates Safety and Potent Antiviral Activity in HCV-Infected Patients
8. Ortho Biotech Reiterates Confidence in PROCRIT(R) (Epoetin alfa) Safety and Efficacy When Used According to Label
9. New Phase 3 Study in Treatment-Naive Adults with HIV Evaluates Efficacy and Safety of Once-Daily PREZISTA(TM)/ritonavir vs. KALETRA(R) as Part of HIV Combination Therapy
10. New Data From Large Safety Analysis of MYCAMINE Shows Favorable Clinical Safety Profile
11. Further Data on Safety and Efficacy of Cethromycin Presented at 47th Interscience Conference on Antimicrobial Agents and Chemotherapy
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2014)... 24, 2014   AcelRx Pharmaceuticals, Inc.  (Nasdaq: ... the development and commercialization of innovative therapies for the ... PDUFA date for Zalviso remains July 27, 2014.  ... online stating the Food and Drug Administration (FDA) had ... been no notification to the company from the FDA ...
(Date:7/24/2014)... HILDEN , Germany , and ... , Exclusive global ... assays for SF3B1 mutations, including next-generation sequencing (NGS) gene ... gene, to be targeted by new test, indicate favorable ... myelodysplastic syndromes  QIAGEN sees potential for developing ...
(Date:7/24/2014)... -- Amgen (NASDAQ: AMGN ) today announced that ... July 29, 2014, after the close of the U.S. financial ... with the investment community at 2 p.m. PT. Participating in ... , chairman and chief executive officer, and other members of ... conference call will be simultaneously broadcast over the Internet and ...
Breaking Medicine Technology:AcelRx Pharmaceuticals Confirms July 27, 2014 PDUFA Date for Zalviso 2QIAGEN Adds Promising Genomic Biomarkers for Assessing Prognosis in Treatment of Blood Cancers to Personalized Healthcare Pipeline 2QIAGEN Adds Promising Genomic Biomarkers for Assessing Prognosis in Treatment of Blood Cancers to Personalized Healthcare Pipeline 3QIAGEN Adds Promising Genomic Biomarkers for Assessing Prognosis in Treatment of Blood Cancers to Personalized Healthcare Pipeline 4QIAGEN Adds Promising Genomic Biomarkers for Assessing Prognosis in Treatment of Blood Cancers to Personalized Healthcare Pipeline 5Amgen Announces Webcast of 2014 Second Quarter Financial Results 2
...  The advanced functionality of Elekta,s family of digital ... coordination. Elekta,s latest control system, Integrity™ R1.1, meets ... of MLC interdigitation for exceptional field shaping, and ... radiation dose. Integrity ...
... Inc. (NASDAQ: VSCP ), a leading provider of ... Markin, the company,s president and chief executive officer, will be ... CEO & Investor Conference at the Waldorf Astoria in New ... 13, 2012 at 4:30 PM ET. A live ...
Cached Medicine Technology:Sixth Generation Elekta Digital Control System Boosts Radiation Therapy System Speed and Performance 2VirtualScopics to Present at the 14th Annual BIO CEO & Investor Conference 2
(Date:7/26/2014)... According to the Banish My Bumps ... comprehensive guide that covers detailed instructions on how to ... need of any medication. , Vkool reveals in ... safe remedies for relieving symptoms of keratosis pilaris quickly. ...     How to treat children's keratosis pilaris , ...
(Date:7/25/2014)... Staffordshire, UK (PRWEB) July 26, 2014 ... a variety of dental services including general dentistry, clear ... practice opening in September this year in Derby. The ... is at the HollyBrook Medical Centre in Littleover, Derby. ... the new practice. , The new dental practice, which ...
(Date:7/25/2014)... In recent years, men have become more ... the symptoms associated with age-related testosterone decline. Amid concerns about ... new case study from Renew Man helps to ... using bioidentical hormones. , The case study centers around ... found himself beginning to feel the effects of age-related hormonal ...
(Date:7/25/2014)... July 25, 2014 As reported by the ... War On Heroin (7/20), police in Salem, MA as ... down on the recent heroin epidemic that has taken many ... on one heroin-related overdose case in which police were able ... victim's cell phone. By pretending to be the victim and ...
(Date:7/25/2014)... 2014 (HealthDay News) -- Seniors are more easily distracted ... new study finds. "Almost any type of memory ... age of 25 on," study co-author Randi Martin, professor ... news release. However, Martin said, this study shows ... in older adults compared with younger adults. The ...
Breaking Medicine News(10 mins):Health News:Banish My Bumps Pdf Review Exposes Angela Steinberg's Keratosis Pilaris Treatment Plan – Vkool.com 2Health News:Banish My Bumps Pdf Review Exposes Angela Steinberg's Keratosis Pilaris Treatment Plan – Vkool.com 3Health News:Derby Cosmetic Dentist Dental Perfection to Open New Practice in Littleover, Derby this September 2Health News:New Case Study Highlights Effectiveness of Testosterone Therapy in Fighting Weight Gain and Fatigue 2Health News:New Case Study Highlights Effectiveness of Testosterone Therapy in Fighting Weight Gain and Fatigue 3Health News:Multiple States Crack Down on Heroin Epidemic 2Health News:Distractions Seem More Troublesome With Age 2
... made from some of the same parts used in ... way to measure the growth and drug susceptibility of ... The new biosensor promises to speed treatment of ... Smalley Distinguished University Professor of Chemistry, Physics and Applied ...
... Thea Friedman, M.D., associate scientist and director of ... at Hackensack University Medical Center was recently awarded a ... RO1 research grant to improve allogeneic blood and marrow ... $2 million in funding over the next five years. ...
... a successful Phase 1 study for safety, researchers at ... today announced the beginning of a Phase 2 clinical ... they developed to prevent hepatitis C virus (HCV) ... The first patients were enrolled in the study in ...
... - A recent study by Merikangas and colleagues published ... of the American Academy of Child and Adolescent Psychiatry ... are affected with severely impairing mental disorders ever receive ... that approximately one third of adolescents with any mental ...
... researchers have used a type of brain scanning, known as ... in blood flow in the brain and to correlate this ... data, which could improve is reported in the International ... have known since the 1890s that changes in blood flow ...
... risk factors for breast cancer are well studied and documented. ... period, late onset of menopause and a family history of ... However, neither an individual woman nor medicine can influence ... menopause starts - these are risk factors on which we ...
Cached Medicine News:Health News:See how they grow: Monitoring single bacteria without a microscope 2Health News:See how they grow: Monitoring single bacteria without a microscope 3Health News:Oncology basic research director at John Theurer Cancer Center continues transplantation research 2Health News:First liver transplant patients receive experimental drug to prevent hepatitis C infection 2Health News:First liver transplant patients receive experimental drug to prevent hepatitis C infection 3Health News:Adolescents with severe mental disorders have never received treatment 2Health News:Functional boost for magnetic resonance imaging 2Health News:Scientists identify avoidable breast cancer risk factors 2
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
Medicine Products: